SCHEMBL6284223

SCHEMBL6284223

COc1ccc(-c2nc3ccnnc3[nH]2)cc1NC(N)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 1/20 0.44
ALDH1A1 P00352 5/20 0.43
KDM4E B2RXH2 3/20 0.43
GUSB P08236 2/20 0.43
HPGD P15428 2/20 0.43
CDK4 P11802 1/20 0.43
CCND1 P24385 1/20 0.43
AMY1A P0DUB6 3/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
LMNA P02545 2/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
PARP1 P09874 1/20 0.40
HPSE Q9Y251 1/20 0.40
SLC9A1 P19634 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286122 0.85 CDK4 (0.49) VCPALDH1A1KDM4EGUSBHPGD
SCHEMBL6278620 0.84 PARP1 (0.49) ALDH1A1KDM4EGUSBHPGDAMY1A
SCHEMBL6282536 0.82 ALDH1A1 (0.68) VCPALDH1A1KDM4EHPGDAMY1A
SCHEMBL6283028 0.81 ALDH1A1 (0.49) VCPALDH1A1KDM4EGUSBHPGD
SCHEMBL6286384 0.80 CDK4 (0.45) VCPALDH1A1KDM4EGUSBHPGD
SCHEMBL6278625 0.80 KDM4E (0.46) ALDH1A1KDM4EGUSBHPGDAMY1A
SCHEMBL6288126 0.80 AMY1A (0.40) VCPALDH1A1KDM4EHPGDCDK4
SCHEMBL6286020 0.80 VCP (0.48) VCPALDH1A1KDM4ECDK4CCND1
SCHEMBL6288124 0.79 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDAMY1AKMT2A
SCHEMBL6709551 0.74 SMN1; SMN2 (0.54) ALDH1A1KDM4EHPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP claimed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B VCP 4841/4885ALDH1A1 522/4885KDM4E 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.